Trial Profile

An exploratory study of SHR-1701 in combination with Famitinib in patients with Advanced Pancreatic cancer and Biliary Tract Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Famitinib (Primary) ; Retlirafusp alfa (Primary)
Indications Adenocarcinoma; Biliary cancer; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use

30 Apr 2025 Results presented at the 116th Annual Meeting of the American Association for Cancer Research
25 Oct 2024 Results (n=45;as of May 1, 2024) evaluating the efficacy and safety of SHR-1701 combined with famitinib in patients with advanced BTC or PDAC who failed previous standard treatment presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
22 Jan 2022 Results (as of 15 Sep 2021; n= 24) presented at the 2022 Gastrointestinal Cancers Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com